Case series of rosiglitazone used during the first trimester of pregnancy.
Reprod Toxicol
; 26(2): 183-4, 2008 Oct.
Article
in En
| MEDLINE
| ID: mdl-18762242
Prior to 2007, use of the insulin sensitizer metformin was widely advocated in patients with polycystic ovarian syndrome (PCOS) both to promote ovulation and decrease the incidence of PCOS-associated obstetrical complications. However, the gastrointestinal disturbances associated with metformin led many to discontinue its use. Rosiglitazone is an insulin sensitizer that, because of minimal associated gastrointestinal disturbance, was used as an alternative to metformin in PCOS patients. From 2003 to 2005, 8 women with PCOS unable to tolerate metformin used rosiglitazone for ovulation induction and during their first 12 weeks of gestation. All delivered healthy babies at term, without obstetric complications or congenital anomalies. However, given recent evidence that disputes the reproductive benefits of insulin sensitization for PCOS and that raises safety concerns of rosiglitazone, we are no longer using it for PCOS treatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovulation
/
Ovulation Induction
/
Polycystic Ovary Syndrome
/
Thiazolidinediones
/
Hypoglycemic Agents
/
Anovulation
Type of study:
Etiology_studies
Limits:
Adult
/
Female
/
Humans
/
Newborn
/
Pregnancy
Language:
En
Journal:
Reprod Toxicol
Journal subject:
EMBRIOLOGIA
/
MEDICINA REPRODUTIVA
/
TOXICOLOGIA
Year:
2008
Document type:
Article
Affiliation country:
United States
Country of publication:
United States